Phacilitate Announces the Inauguration of First Gala Awards Dinner to Celebrate the Achievements of the Advanced Therapies Field
Phacilitate answers industry’s call for sector-specific celebration ceremony.
Phacilitate, the member network connecting industry leaders across the advanced therapies industry, today announces the inauguration of Advanced Therapies Awards. The Phacilitate Advanced Therapies Awards have been curated in response to industry feedback citing the need for a celebration of recognition, specifically for the advanced therapies industry.
Phacilitate will host the awards dinner during Advanced Therapies Week in Miami, US, January 19, 2023. The event will be in the format of a black-tie, gala dinner, celebrating the achievements and progress made by individuals and teams working within the advanced therapies industry, as well as providing further opportunity for the industry to come together.
“Our mission at Phacilitate is to help every biotech on their commercialization journey. The awards will recognize those biotech and technology companies that are doing outstanding work, and it is through this recognition that we hope to forge partnerships and connections that are vital for getting these treatments into patients,” explained Kim Barnes, Executive Vice President, Phacilitate.
“Our extensive network of partners from across the advanced therapies sector will provide us with the perfect platform to host the first major awards ceremony in the field. Advanced therapies are life-changing treatments for patients suffering from life threatening and chronic conditions, including cancer. It is therefore important to celebrate the successes and achievements of those within the field; who are helping to bring these therapies to patients across the globe,” Kim continued.
Submissions for the awards are now open to the public, for the nomination of individuals who have made an exceptional contribution to the advanced therapies field. Nominations can be submitted here.
All nominations will be reviewed by a panel of expert judges from the sector, including Dr Bruce Levine, Barbara and Edward Netter Professor in Cancer Gene Therapy at the University of Pennsylvania and former ISCT President, David Lennon, President at Novartis Gene Therapies and Tom Whitehead, Founder of the Emily Whitehead Foundation, along with a host of other esteemed leaders from the industry. The closing date for submissions will be 9 September 2022, with the finalized shortlist announced on 27 October 2022.
During the event, Phacilitate will award Dr Carl H. June, M.D., Richard W Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine at the Perelman School of Medicine of the University of Pennsylvania, the inaugural Advanced Therapies Lifetime Achievement Award. Phacilitate has recognized Dr June as a pioneer within the field of immunotherapy, having been instrumental in the development of T-cell therapies in the treatment of cancer. Dr June’s work has also led to the development and commercialization of Tisagenlecleucel®, the first FDA-approved gene therapy.
Source: Phacilitate press release
About Advanced Therapies Week
Advanced Therapies Week brings the global advanced therapies community together for the most important week for doing business in advanced therapies. Home to the largest marketplace for tools and tech, Advanced Therapies Week is dedicated to helping biotech progress on their commercialization journey, as well as pushing the industry one step closer to delivering life changing treatments to patients.
Advanced Therapies Week was created for knowledge sharing, relationship building and deal making; through the connections you create and the knowledge you share, you help advance the next pillar of medicine.
Find out more, visit: https://advancedtherapiesweek.phacilitate.com
Phacilitate connects industry leaders through inspiring conferences, vibrant communities and market intelligence. Phacilitate organises conferences and networking events in both Europe and the US. These provide a venue for the advanced therapies sector seeking the commercialisation of global therapies and a global audience expanding further into the various markets worldwide.
Phacilitate provides market insights and resources to the advanced therapies industry. These market insights have specific focuses on industry insights that range from trials, finance and investment, regulation, manufacturing, and specific therapeutic techniques.
Find out more, visit: www.phacilitate.com